Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Best 7 Multi-CDN Providers in 2026

Multi-CDN has moved from backup plan to core delivery architecture. This guide ranks the 7 best Multi-CDN providers of 2026, led by IO River, and breaks down steering, behavioral consistency, observability, and governance factors that determine real resilience.
The team of Treeview, one of the leading AR and VR comapnies, wearing virtual reality glasses

25 VR and Augmented Reality Development Companies in 2026

Explore the top 25 best virtual reality (VR) and augmented reality (AR) development companies in the world

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.

Best 5 Israeli VCs Active in MedTech and Digital Health

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Top Sustainable Packaging Companies 2026

Top Sustainable Packaging Companies 2026

Find the best sustainable packaging companies of 2026. From seaweed to molded fiber, compare materials, formats, and what actually works.
Top Defense Tech Startups Building the Next Generation of Military Technology

Top Defense Tech Startups Building the Next Generation of Military Technology

Anduril, Saronic, Helsing, and more: a close look at the defense tech startups building the next generation of military technology.
Best Tech Marketing Agencies in 2026

Best Tech Marketing Agencies in 2026

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Read full story

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
16 Robotics Unicorns in 2026

16 Robotics Unicorns in 2026

Meet the 16 private robotics companies valued at $1B+ in 2026, from humanoid robots to defense autonomy and warehouse systems.
Healthtech Unicorns to Consider in 2026

Healthtech Unicorns to Consider in 2026

The healthtech unicorns worth watching in 2026 are tied to real care needs. Here are the private companies investors still take seriously.
10 Biotech Unicorn Startups to Watch in 2026

10 Biotech Unicorn Startups to Watch in 2026

Meet the private biotech companies valued at $1 billion or more in 2026 and find out what still makes them worth watching.
10 Insurtech Unicorn Companies to Watch in 2026

10 Insurtech Unicorn Companies to Watch in 2026

Discover the 10 insurtech unicorn companies shaping private insurance in 2026, from cyber specialists to embedded platforms.
14 Edtech Unicorns to Consider in 2026

14 Edtech Unicorns to Consider in 2026

Which edtech companies are still worth watching in 2026? We break down 14 private unicorns across training, language, and career tech.
Fintech Unicorns Around the World to Watch in 2026

Fintech Unicorns Around the World to Watch in 2026

Stripe, Revolut, Klarna, Ramp, and more. A clear look at the private fintech unicorns still worth watching in 2026.
Cybersecurity Unicorns Around the World to Watch in 2026

Cybersecurity Unicorns Around the World to Watch in 2026

The top private cybersecurity companies worth watching in 2026, from data security to supply chain protection. Valuations, funding, and what they actually do.
Read full story

Explore our collection of top interviews

Dive into our thoughtfully curated selection of insightful and impactful interviews with leaders and innovators in their fields.
Maisa CEO David Villalón

AI Costs Aren't the Problem. Enterprise AI Architecture Is, Says Maisa CEO David Villalón

Maisa CEO David Villalón explains why enterprise AI costs stem from poor architecture, not model pricing, and how multi-model systems fix it.
Carl Livie is Co-Founder and Chief Executive Officer of JustPlay

Inside JustPlay’s Vision for the Next Generation of Reward Ecosystems

JustPlay CEO Carl Livie explains how rewarded gaming can create sustainable value for players through a fully integrated ecosystem.
Encube

Interview with Hugo Nordell, CEO of Encube: Rethinking hardware manufacturing workflows

Hugo Nordell of Encube on why AI-powered hardware development tools are now essential for European manufacturers facing talent gaps and supply chain shifts.
Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Victor Folmann on why gaming communities, not studios, will shape the next generation of games and how Chosen is betting on that.
Interview: Zakhar Azatian, CEO & Founder, BeHard

Interview: Zakhar Azatian, CEO & Founder, BeHard

Zakhar Azatian built BeHard to 1M users and $490K MRR with no outside funding. Here's the growth system behind it.
Will Weise

A Breakthrough Bongo Antelope Birth Shows How Reproductive Technology Could Help Stop Extinction

Critically endangered Bongo antelope born to Eland surrogate in Texas breakthrough. Dr. Will Weise explains how reproductive tech fights extinction.

Shaping Fintech’s Next Chapter: An Interview with Oleg Seitov, Head of Finance at xpate

xpate's Head of Finance Oleg Seitov shares insights on balancing fintech innovation with discipline, AI automation, and sustainable growth strategies.
Read full story

Discover our top blog articles

Explore our carefully curated selection of engaging and informative blog articles on a variety of topics.
The Best 10 PR Agencies in Europe 2027

The Best 10 PR Agencies in Europe 2027

Discover the 10 best PR agencies in Europe for 2027. Compare their specialties, international reach, services, and proven client results.
Best PR agencies for Series A, B and C SaaS companies

Best PR agencies for Series A, B and C SaaS companies

Explore 12 PR agencies for Series A, B and C SaaS companies. Compare industry expertise, funding campaign experience and media relations services.

Aircraft Management Costs Explained: Crew, Maintenance, Hangar, and Operations

Private aircraft ownership costs go far beyond the purchase price. This guide breaks down crew, maintenance, hangar, fuel, and insurance expenses, and explains how understanding fixed versus variable costs helps owners budget accurately and avoid surprises.

Best Sovereign Cloud Providers in Europe

Compare the 10 best sovereign cloud providers in Europe for 2026, including Ilkari, OVHcloud, Scaleway, IONOS, AWS, Microsoft and more.
Best Sovereign Cloud Providers in Latin America

Best Sovereign Cloud Providers in Latin America

Compare 10 leading sovereign cloud providers in Latin America, including regional, government and global options for regulated workloads.

Three Reasons to Have Digital Signage

Digital signage gives businesses a flexible alternative to printed signs, with content that updates instantly and engages more effectively. This guide covers three reasons to make the switch, from stronger communication and fresher content to a more polished customer experience.

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.
Read full story

Why GV and Intrepid Growth Partners Backed Iterative Health's $77M Round

Key Points
  • Iterative Health raised $77 million in Series C funding led by Intrepid Growth Partners and GV, with EDBI, Insight Partners, and Obvious Ventures also participating.
  • The company runs an AI-assisted clinical research network across 100 sites in four continents, reporting three times higher IBD patient enrollment than industry benchmarks.
  • New funding will expand Iterative Health's network into cardiology and obesity, building on its established base in gastroenterology and hepatology.
April 30, 2026
Jonathan Ng
Credits: Obvious Ventures

Funding details

Iterative Health, a healthcare technology and services company based in Cambridge, Massachusetts, has closed a $77 million Series C financing round to expand its AI-assisted clinical research network. Founded in 2017 by Jonathan Ng, MBBS, the company works with physician practices to run clinical trials more efficiently, connecting drug developers with research sites and the patients those sites can reach.

Getting a new drug to market takes more than good science. It takes a system of research sites that can find patients, enroll them quickly, and keep studies on track. That system is failing in measurable ways. Roughly 80% of clinical trials face delays because of recruitment problems and dropout rates. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials miss their enrollment targets on time. For patients waiting on new treatments, those delays have real consequences.

The Series C was co-led by Intrepid Growth Partners and GV (Google Ventures). New investors include EDBI, the investment arm of SG Growth Capital backed by Enterprise Singapore and the Economic Development Board, along with a prominent family office. Existing backers Insight Partners and Obvious Ventures also participated.

How Iterative Health Runs Clinical Trials Differently

Most efforts to improve clinical trial performance have targeted isolated problems: better recruitment tools, faster regulatory filings, improved patient tracking. Iterative Health's approach is broader. The company places what it calls site success at the center of trial execution, providing research sites with centralized operations, trained staff, and proprietary AI tools so they can focus on running studies rather than managing logistics.

The results the company reports are worth noting. Compared to industry benchmarks for inflammatory bowel disease trials, Iterative Health's network activates research sites twice as fast, cutting startup timelines by up to three months. Patient enrollment runs at three times the typical rate. Across its global site network, more than two IBD patients are randomized on average every business day.

"Clinical research remains the biggest bottleneck in drug development today. Iterative Health is solving this by using AI to accelerate trial enrollment times and bring new medicines to market faster. Jonathan and his team possess the technical depth and operational expertise needed to tackle clinical trial complexity at scale, and we're excited to support Iterative Health as they expand to new therapeutic areas." — Anthony Philippakis, General Partner of GV.

Where the New Funding Will Go

Iterative Health has built its network primarily around gastroenterology and hepatology, two fields focused on digestive and liver conditions. The new capital will support expansion into cardiology and obesity, areas where the company has recently begun operations, as well as continued geographic growth. The network currently includes more than 100 research sites across North America, Europe, India, and Australia.

The company will also deepen its partnerships with provider organizations. It already works with GI Alliance, OneGI, and US Heart & Vascular, and plans to bring more practices into its network. The aim is to reach community-based clinics where patients already receive care, rather than concentrating research in a small number of specialist centers.

As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health's Board of Directors. Anthony Philippakis, General Partner at GV (Google Ventures), will join as a board observer.

What Iterative Health Does and How It Works

Iterative Health was founded with the goal of making clinical research a standard part of how physicians care for patients, not a separate, complicated undertaking that most practices cannot afford to support. The company employs more than 250 people globally across its Cambridge headquarters and New York City offices.

Its model gives physician practices access to the infrastructure they need to participate in trials: staffing support, regulatory guidance, and operational tools. One of those tools is SKOUT, an AI platform that helps identify eligible patients by analyzing endoscopic images and clinical data. Finding the right patients is often where trials stall, and SKOUT is designed to speed that process up. Sites working with Iterative Health can take on more studies with less operational strain, which is part of why the company's enrollment numbers outperform the industry average.

"Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we've built a system that delivers high-performance site execution at scale." — Jonathan Ng, MBBS, Founder and CEO, Iterative Health.

The network now includes partnerships with more than 40 pharmaceutical, biotech, medical device, and contract research organizations.

The Investors Behind the Round

This Series C is Iterative Health's third known institutional funding round. The company previously raised a Series B in early 2022, in which Insight Partners and Obvious Ventures both participated. Both firms returned for the current round.

Intrepid Growth Partners is a growth equity firm with offices in Toronto and London that focuses on AI-enabled companies. GV is Alphabet's venture capital arm and has invested across life sciences and health technology for over a decade.

"Intrepid invests in growth-stage companies that harness the power of AI to execute profound system redesigns that vastly enhance productivity across their industry. Iterative Health is a perfect example of this thesis, having purpose-built its proprietary technology to power a revolutionary clinical trial network that delivers unparalleled speed and scale to the pharmaceutical sector." — Ajay Agrawal, Co-Founder and Partner, Intrepid Growth Partners.

Funding details

Subscribe to our newsletter

Subscribe

Last related articles

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram